Plasma levels and postpartum breastmilk concentrations of sugammadex: a pharmacokinetic study in women undergoing general anaesthesia for caesarean delivery
Authors' conclusion
The volume of distribution and clearance of rocuronium and sugammadex were at the upper end of published ranges from non-pregnant patients. Sugammadex was not detected or was below the lower limit of quantification in all breastmilk samples, providing reassurance regarding infant exposure in the early post-partum period.
Study context
- Population
- Pregnant women having scheduled caesarean delivery under GA at term, given rocuronium at induction and sugammadex for reversal of NMBfour (40%) nulliparous
- Participants
- 10 women
- Outcome
- Pharmacokinetics of sugammadex, including breastmilk excretion
- Follow-up
- Up to 24 h after sugammadex
Methodological detailspopulation pharmacokinetic analysis, two-compartment model
- Population pharmacokinetic analysis
- Two-compartment model
Main finding
As reported in the abstract
Pharmacokinetic parameters and breastmilk excretion
- Rocuronium volume of distribution
- 17.9 L
- Rocuronium clearance
- 12.6 L/h
- Sugammadex volume of distribution
- 13.9 L
- Sugammadex clearance
- 8.0 L/h
- Breastmilk samples with sugammadex detected (up to six hours), each below limit of quantification
- 12.5%
Original publication
Plasma levels and postpartum breastmilk concentrations of sugammadex: a pharmacokinetic study in women undergoing general anaesthesia for caesarean delivery. Int J Obstet Anesth. Published 21 February 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →